文献速递前列腺癌

活检初治疑似前列腺癌男性中风险适配超声引导与磁共振引导诊断路径的前瞻性多中心比较研究

A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.
PubMed 文献 · Eur Urol · 2022-03-24

这项前瞻性多中心研究将1965例活检初治疑似前列腺癌男性1:1分配至超声引导路径(RPCRC#3评估,950例)或磁共振引导路径(PI-RADS 3-5分,1015例)。两组检出GG≥2癌比例相当(25% vs 24%,差异1.2%,95%CI -2.6%至5.0%,p=0.5),超声路径检出更多GG 1癌(13% vs 8.3%),磁共振路径避免更多活检(55% vs 42%)。

要点

  • 风险适配超声引导与磁共振引导路径检出GG≥2前列腺癌效果相当(25% vs 24%,p=0.5)。
  • 超声路径检出更多GG 1癌(13% vs 8.3%),磁共振路径避免更多活检(55% vs 42%)。
  • 高危人群中磁共振组检出更多GG≥2癌(52% vs 43%,差异9.2%,95%CI 3.0-15%,p<0.01)。

核心结论

  • 风险适配超声引导与磁共振引导路径检出GG≥2前列腺癌效果相当。
  • 若无前列腺磁共振条件与经验,风险适配超声引导路径诊断表现良好。
  • 若磁共振可及性充足,风险分层宜优先采用磁共振,因其避免更多活检且检出更少GG 1癌。

研究设计与样本

  • 前瞻性多中心研究(MR-PROPER),21个中心按1:1分配,超声组11个中心、磁共振组10个中心。
  • 纳入活检初治疑似前列腺癌男性,年龄≥50岁,前列腺特异性抗原3.0-50 ng/ml,±直肠指检异常。
  • 意向治疗人群共1965例,超声组950例,磁共振组1015例。

主要发现

  • 超声组与磁共振组检出GG≥2癌比例相当:235/950(25%)vs 239/1015(24%),差异1.2%,95%CI -2.6%至5.0%,p=0.5。
  • 超声组检出GG 1癌多于磁共振组:121/950(13%)vs 84/1015(8.3%),差异4.5%,95%CI 1.8-7.2%,p<0.01。
  • 超声组避免活检少于磁共振组:403/950(42%)vs 559/1015(55%),差异-13%,95%CI -17%至-8.3%,p<0.01。
  • 高危人群中磁共振组检出GG≥2癌多于超声组:52% vs 43%,差异9.2%,95%CI 3.0-15%,p<0.01。

临床怎么用

  • 欧洲泌尿外科学会指南推荐对活检初治男性采用风险适配的活检策略以早期发现前列腺癌。
  • 作者认为,若无前列腺磁共振条件与经验,风险适配超声引导路径诊断表现良好。
  • 作者认为,若磁共振可及性充足,风险分层宜优先采用磁共振,以避免更多活检并检出更少GG 1癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: European Association of Urology guidelines recommend a risk-adjusted biopsy strategy for early detection of prostate cancer in biopsy-naïve men. It remains unclear which strategy is most effective. Therefore, we evaluated two risk assessment pathways commonly used in clinical practice. OBJECTIVE: To compare the diagnostic performance of a risk-based ultrasound (US)-directed pathway (Rotterdam Prostate Cancer Risk Calculator [RPCRC] #3; US volume assessment) and a magnetic resonance imaging (MRI)-directed pathway. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective multicenter study (MR-PROPER) with 1:1 allocation among 21 centers (US arm in 11 centers, MRI arm in ten). Biopsy-naïve men with suspicion of prostate cancer (age ≥50 yr, prostate-specific antigen 3.0-50 ng/ml, ± abnormal digital rectal examination) were included. INTERVENTION: Biopsy-naïve men with elevated risk of prostate cancer, determined using RPCRC#3 in the US arm and Prostate Imaging Reporting and Data System scores of 3-5 in the MRI arm, underwent systematic biopsies (US arm) or targeted biopsies (MRI arm). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the proportion of men with grade group (GG) ≥2 cancer. Secondary outcomes were the proportions of biopsies avoided and GG 1 cancers detected. Categorical (nonparametric) data were assessed using the Mann-Whitney U test and χ2 tests. RESULTS AND LIMITATIONS: A total of 1965 men were included in the intention-to-treat population (US arm n = 950, MRI arm n = 1015). The US and MRI pathways detected GG ≥2 cancers equally well (235/950, 25% vs 239/1015, 24%; difference 1.2%, 95% confidence interval [CI] -2.6% to 5.0%; p = 0.5). The US pathway detected more GG 1 cancers than the MRI pathway (121/950, 13% vs 84/1015, 8.3%; difference 4.5%, 95% CI 1.8-7.2%; p < 0.01). The US pathway avoided fewer biopsies than the MRI pathway (403/950, 42% vs 559/1015, 55%; difference -13%, 95% CI -17% to -8.3%; p < 0.01). Among men with elevated risk, more GG ≥2 cancers were detected in the MRI group than in the US group (52% vs 43%; difference 9.2%, 95% CI 3.0-15%; p < 0.01). CONCLUSIONS: Risk-adapted US-directed and MRI-directed pathways detected GG ≥2 cancers equally well. The risk-adapted US-directed pathway performs well for prostate cancer diagnosis if prostate MRI capacity and expertise are not available. If prostate MRI availability is sufficient, risk assessment should preferably be performed using MRI, as this avoids more biopsies and detects fewer cases of GG 1 cancer. PATIENT SUMMARY: Among men with suspected prostate cancer, relevant cancers were equally well detected by risk-based pathways using either ultrasound or magnetic resonance imaging (MRI) to guide biopsy of the prostate. If prostate MRI availability is sufficient, risk assessment should be performed with MRI to reduce unnecessary biopsies and detect fewer irrelevant cancers.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wagensveld IM, Osses DF, Groenendijk PM, et al. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men. Eur Urol. 2022. PMID: 35341658. doi:10.1016/j.eururo.2022.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。